Moleculin Biotech, Inc. (MBRX) Financial Statements (2023 and Earlier)

Company Profile

Business Address 5300 MEMORIAL DRIVE
HOUSTON, TX 77007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments70,90315,17310,7357,1347,7145,007
Cash and cash equivalents70,90315,17310,7357,1347,7145,007
Receivables45110   
Prepaid expense5897432,749840588215
Other undisclosed current assets9601,281(10)   
Total current assets:72,49717,19813,4847,9748,3025,222
Noncurrent Assets
Operating lease, right-of-use asset107202287
Property, plant and equipment3384833164633323
Intangible assets, net (including goodwill), including:11,14811,14811,14811,14811,14811,148
Intangible assets, net (excluding goodwill)11,10011,100    
Other undisclosed intangible assets, net (including goodwill)484811,14811,14811,14811,148
Total noncurrent assets:11,59311,83311,75111,61111,18111,171
TOTAL ASSETS:84,09029,03125,23519,58519,48316,393
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,6222,9203,5703,5481,7121,049
Accounts payable1,3641,1292,1531,246810 
Accrued liabilities2,2581,7911,4172,302902 
Interest and dividends payable     7
Other undisclosed accounts payable and accrued liabilities     1,041
Debt     296
Deferred compensation liability   150  
Derivative instruments and hedges, liabilities   180503 
Total current liabilities:3,6222,9203,5703,8782,2151,345
Noncurrent Liabilities
Long-term debt and lease obligation63159276   
Operating lease, liability63159276
Liabilities, other than long-term debt1,4128,1925,8181,43515088
Deferred compensation liability, classified    15088
Deferred rent credit   107
Derivative instruments and hedges, liabilities1,4128,1925,8181,328  
Total noncurrent liabilities:1,4758,3516,0941,43515088
Total liabilities:5,09711,2719,6645,3132,3651,433
Stockholders' equity
Stockholders' equity attributable to parent, including:78,99317,76015,57114,27217,11814,960
Common stock296946292112
Common stock, share subscribed but unissued, subscriptions receivable (129)    
Additional paid in capital151,73374,67155,05540,56431,57719,623
Accumulated deficit(72,810)(56,916)(39,561)(26,356)(14,480)(4,675)
Other undisclosed stockholders' equity attributable to parent41653135  
Total stockholders' equity:78,99317,76015,57114,27217,11814,960
TOTAL LIABILITIES AND EQUITY:84,09029,03125,23519,58519,48316,393

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues
(Other Income)
    9 
Gross profit:    9 
Operating expenses(22,968)(19,742)(17,524)(15,025)(8,653)(3,883)
Other undisclosed operating loss    (9) 
Operating loss:(22,968)(19,742)(17,524)(15,025)(8,653)(3,883)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
402815(40)  
Interest and debt expense     (43)
Loss from continuing operations before equity method investments, income taxes:(22,928)(19,714)(17,509)(15,065)(8,653)(3,926)
Other undisclosed income from continuing operations before income taxes 2,359    
Loss from continuing operations before income taxes:(22,928)(17,355)(17,509)(15,065)(8,653)(3,926)
Income tax benefit  229   
Net loss:(22,928)(17,355)(17,280)(15,065)(8,653)(3,926)
Other undisclosed net income (loss) attributable to parent7,034 4,0753,189(1,152) 
Net loss available to common stockholders, diluted:(15,894)(17,355)(13,205)(11,876)(9,805)(3,926)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(22,928)(17,355)(17,280)(15,065)(8,653)(3,926)
Comprehensive loss:(22,928)(17,355)(17,280)(15,065)(8,653)(3,926)
Other undisclosed comprehensive income, net of tax, attributable to parent7,010344,0713,224  
Comprehensive loss, net of tax, attributable to parent:(15,918)(17,321)(13,209)(11,841)(8,653)(3,926)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: